(600216)"Zhejiang Medicine Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600216 · · 12 pages · Chinese
Summary by 6ix AI
The report indicates significant declines in key financial metrics, including total revenue and net profit attributable to shareholders compared to the previous year. The company has confirmed that the financial statements have not been audited, and it emphasizes the accuracy and completeness of the reported information. The report also highlights the challenges faced due to declining market prices for its main products, which have adversely affected profitability.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Medicine Co., Ltd. on 6ix
Earlier from Zhejiang Medicine
- (600216)"Zhejiang Medicine Co., Ltd."Announcement on Progress in Repurchasing Shares
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Progress in Repurchasing Shares
- Announcement on Resolutions of the 14th Meeting of the 10th Board of Directors
- Announcement on Initial Repurchase of Shares through Call Auction
Follow Zhejiang Medicine into a list and get an email when it puts out news.
Follow Zhejiang Medicine